L
Laura Qm Chow
Researcher at University of Washington
Publications - 14
Citations - 3062
Laura Qm Chow is an academic researcher from University of Washington. The author has contributed to research in topics: Nivolumab & Lung cancer. The author has an hindex of 9, co-authored 14 publications receiving 2395 citations. Previous affiliations of Laura Qm Chow include Fred Hutchinson Cancer Research Center & National Taiwan University.
Papers
More filters
Journal ArticleDOI
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y. Seiwert,Barbara Burtness,Ranee Mehra,Jared Weiss,Raanan Berger,Joseph Paul Eder,Karl Heath,Terrill K. McClanahan,Jared Lunceford,Christine K. Gause,Jonathan D. Cheng,Laura Qm Chow +11 more
TL;DR: Pembrolizumab was well tolerated and demonstrated clinically meaningful antitumour activity in recurrent or metastatic squamous cell carcinoma of the head and neck, supporting further study of pembrolIZumab as anticancer therapy for advancedHead and neck cancers.
Journal ArticleDOI
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
Matthew D. Hellmann,Naiyer A. Rizvi,Jonathan W. Goldman,Scott N. Gettinger,Hossein Borghaei,Julie R. Brahmer,Neal Ready,David E. Gerber,Laura Qm Chow,Rosalyn A. Juergens,Frances A. Shepherd,Scott A. Laurie,William J. Geese,Shruti Agrawal,Tina C. Young,Xuemei Li,Scott J. Antonia +16 more
TL;DR: The primary outcome was safety and tolerability, assessed in all treated patients, and data from the latter two cohorts, which were considered potentially suitable for further clinical development, are presented.
Journal ArticleDOI
Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
Scott N. Gettinger,Naiyer A. Rizvi,Laura Qm Chow,Hossein Borghaei,Julie R. Brahmer,Neal Ready,David E. Gerber,Frances A. Shepherd,Scott J. Antonia,Jonathan W. Goldman,Jonathan W. Goldman,Rosalyn A. Juergens,Scott A. Laurie,Faith E. Nathan,Yun Shen,Christopher T. Harbison,Matthew D. Hellmann +16 more
TL;DR: First-line monotherapy with nivolumab monotherapy demonstrated a tolerable safety profile and durable responses in first-line advanced NSCLC.
Journal ArticleDOI
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.
Ranee Mehra,Ranee Mehra,Tanguy Y. Seiwert,Shilpa Gupta,Shilpa Gupta,Jared Weiss,Iris Gluck,Joseph Paul Eder,Barbara Burtness,Barbara Burtness,Makoto Tahara,Bhumsuk Keam,Hyunseok Kang,Kei Muro,Ravit Geva,Hyun Cheol Chung,Chia Chi Lin,Deepti Aurora-Garg,Archana Ray,Kumudu Pathiraja,Jonathan D. Cheng,Laura Qm Chow,Robert I. Haddad,Robert I. Haddad +23 more
TL;DR: Some patients received 2 years of treatment and the responses were ongoing for more than 30 months; the durable anti-tumour activity and tolerable safety profile, observed with long-term follow-up, support the use of pembrolizumab as a treatment for recurrent/metastatic HNSCC.
Journal ArticleDOI
57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC.
Don L. Gibbons,Laura Qm Chow,Dong Wook Kim,Sang We Kim,Tammie C. Yeh,X. Song,H. Jiang,Rosemary Taylor,Joyson Joseph Karakunnel,Benjamin C. Creelan +9 more
TL;DR: D 10mg/kg plus G 250mg was generally tolerated, with encouraging activity observed in TKI naïve NSCLC pts with sensitising EGFR mutations, supporting continued evaluation of this combination, and primary endpoint: safety and tolerability.